Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer

As a member of helix–loop–helix protein family, transcription factor 12 functions as either an oncogene or a tumor suppressor in various human cancers. However, there are no reports on its involvement in prostate cancer. To investigate clinical relevance of transcription factor 12 in prostate cancer...

Full description

Saved in:
Bibliographic Details
Main Authors: Qing-biao Chen, Ying-ke Liang, Yan-qiong Zhang, Min-yao Jiang, Zhao-dong Han, Yu-xiang Liang, Yue-ping Wan, Jie Yin, Hui-Chan He, Wei-de Zhong
Format: Article
Language:English
Published: SAGE Publishing 2017-06-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317703924
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849428737188167680
author Qing-biao Chen
Ying-ke Liang
Yan-qiong Zhang
Min-yao Jiang
Zhao-dong Han
Yu-xiang Liang
Yue-ping Wan
Jie Yin
Hui-Chan He
Wei-de Zhong
author_facet Qing-biao Chen
Ying-ke Liang
Yan-qiong Zhang
Min-yao Jiang
Zhao-dong Han
Yu-xiang Liang
Yue-ping Wan
Jie Yin
Hui-Chan He
Wei-de Zhong
author_sort Qing-biao Chen
collection DOAJ
description As a member of helix–loop–helix protein family, transcription factor 12 functions as either an oncogene or a tumor suppressor in various human cancers. However, there are no reports on its involvement in prostate cancer. To investigate clinical relevance of transcription factor 12 in prostate cancer and to evaluate its roles in malignant phenotypes of this cancer in vitro and in vivo, we here examined expression patterns of transcription factor 12 protein in 50 prostate cancer tissue specimens by immunohistochemistry. Then, associations of transcription factor 12 expression with various clinicopathological characteristics and patients’ prognosis of prostate cancer were evaluated. Its involvements in cancer cell proliferation, migration, invasion, and tumor growth were determined by in vitro and in vivo experiments. As a result, the positive immunostaining of transcription factor 12 protein was localized in cytoplasm and/or nucleus of prostate cancer cells. Its expression levels were decreased with prostate cancer Gleason score increased. Statistically, the decreased expression of transcription factor 12 protein more frequently occurred in prostate cancer patients with high Gleason score, positive metastasis, prostate-specific antigen failure, and short biochemical recurrence–free survival (all p < 0.05). Importantly, multivariate analysis showed that the status of transcription factor 12 expression was an independent predictor of biochemical recurrence–free survival in prostate cancer. Functionally, enforced expression of transcription factor 12 suppressed cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo. In conclusion, transcription factor 12 protein may be a novel molecule which plays a critical role in prostate cancer progression and patients’ prognosis, suggesting it might be a promising therapeutic target for prostate cancer therapy.
format Article
id doaj-art-3338c7bd8b9349b8a09aef6c8d6406fb
institution Kabale University
issn 1423-0380
language English
publishDate 2017-06-01
publisher SAGE Publishing
record_format Article
series Tumor Biology
spelling doaj-art-3338c7bd8b9349b8a09aef6c8d6406fb2025-08-20T03:28:37ZengSAGE PublishingTumor Biology1423-03802017-06-013910.1177/1010428317703924Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancerQing-biao Chen0Ying-ke Liang1Yan-qiong Zhang2Min-yao Jiang3Zhao-dong Han4Yu-xiang Liang5Yue-ping Wan6Jie Yin7Hui-Chan He8Wei-de Zhong9Department of Urology, Huadu District People’s Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, ChinaChina Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Urology, Huadu District People’s Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, ChinaDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, ChinaDepartment of Urology, Huadu District People’s Hospital, Southern Medical University, Guangzhou, ChinaAffiliated Foshan Hospital of Southern Medical University, Southern Medical University, Foshan, ChinaUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaAs a member of helix–loop–helix protein family, transcription factor 12 functions as either an oncogene or a tumor suppressor in various human cancers. However, there are no reports on its involvement in prostate cancer. To investigate clinical relevance of transcription factor 12 in prostate cancer and to evaluate its roles in malignant phenotypes of this cancer in vitro and in vivo, we here examined expression patterns of transcription factor 12 protein in 50 prostate cancer tissue specimens by immunohistochemistry. Then, associations of transcription factor 12 expression with various clinicopathological characteristics and patients’ prognosis of prostate cancer were evaluated. Its involvements in cancer cell proliferation, migration, invasion, and tumor growth were determined by in vitro and in vivo experiments. As a result, the positive immunostaining of transcription factor 12 protein was localized in cytoplasm and/or nucleus of prostate cancer cells. Its expression levels were decreased with prostate cancer Gleason score increased. Statistically, the decreased expression of transcription factor 12 protein more frequently occurred in prostate cancer patients with high Gleason score, positive metastasis, prostate-specific antigen failure, and short biochemical recurrence–free survival (all p < 0.05). Importantly, multivariate analysis showed that the status of transcription factor 12 expression was an independent predictor of biochemical recurrence–free survival in prostate cancer. Functionally, enforced expression of transcription factor 12 suppressed cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo. In conclusion, transcription factor 12 protein may be a novel molecule which plays a critical role in prostate cancer progression and patients’ prognosis, suggesting it might be a promising therapeutic target for prostate cancer therapy.https://doi.org/10.1177/1010428317703924
spellingShingle Qing-biao Chen
Ying-ke Liang
Yan-qiong Zhang
Min-yao Jiang
Zhao-dong Han
Yu-xiang Liang
Yue-ping Wan
Jie Yin
Hui-Chan He
Wei-de Zhong
Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer
Tumor Biology
title Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer
title_full Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer
title_fullStr Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer
title_full_unstemmed Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer
title_short Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer
title_sort decreased expression of tcf12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer
url https://doi.org/10.1177/1010428317703924
work_keys_str_mv AT qingbiaochen decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT yingkeliang decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT yanqiongzhang decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT minyaojiang decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT zhaodonghan decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT yuxiangliang decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT yuepingwan decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT jieyin decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT huichanhe decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer
AT weidezhong decreasedexpressionoftcf12contributestoprogressionandpredictsbiochemicalrecurrenceinpatientswithprostatecancer